We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$11.5B
1-Year Est. Return
168.77%
This Fund
S&P 500
This Quarter
Est. Return
-8.67%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$4.42B
AUM Growth
-$513M
(-10%)
Cap. Flow
+$279M
Cap. Flow
% of AUM
6.32%
Top 10 Holdings %
Top 10 Hldgs %
50.32%
Holding
73
New
3
Increased
13
Reduced
2
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVAC
CureVac
CVAC
|
+$107M |
| 2 |
Vaxcyte
PCVX
|
+$60.8M |
| 3 |
Mineralys Therapeutics
MLYS
|
+$53.5M |
| 4 |
Geron
GERN
|
+$52.9M |
| 5 |
Pliant Therapeutics
PLRX
|
+$50.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$83.8M |
| 2 |
AKRO
Akero Therapeutics
AKRO
|
+$52.6M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
+$25M |
| 4 |
DALS
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
|
+$15M |
| 5 |
Celldex Therapeutics
CLDX
|
+$14.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.99% |
| 2 | Miscellaneous | 0.01% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma A/S
ASND
$15.8B
| $746M | 16.89% |
6,957,179
| – | – |
|
|
2
Vaxcyte
PCVX
$8.81B
| $273M | 6.19% |
7,291,254
+1,433,795
| +24% | +$60.8M |
|
|
DICE
3
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $225M | 5.1% |
7,856,612
+1,007,701
| +15% | +$29.8M |
|
|
ETNB
4
DELISTED
89bio
ETNB
| $174M | 3.94% |
11,416,948
+2,461,538
| +27% | +$32.1M |
|
|
JBIO
5
Jade Biosciences
JBIO
$1.11B
| $167M | 3.77% |
236,114
| – | – |
|
6
Biogen
BIIB
$31.9B
| $148M | 3.35% |
532,892
| – | – |
|
|
VRNA
7
DELISTED
Verona Pharma
VRNA
| $127M | 2.87% |
6,317,990
| – | – |
|
8
Cytek Biosciences
CTKB
$636M
| $123M | 2.78% |
13,381,054
| – | – |
|
9
Vor Biopharma
VOR
$1.32B
| $122M | 2.77% |
1,137,444
| – | – |
|
10
Legend Biotech
LEGN
$3.44B
| $117M | 2.66% |
2,436,223
| – | – |
|
11
Tyra Biosciences
TYRA
$1.52B
| $116M | 2.63% |
7,236,454
| – | – |
|
12
Janux Therapeutics
JANX
$1.01B
| $105M | 2.38% |
8,670,644
| – | – |
|
13
PepGen
PEPG
$200M
| $99.5M | 2.25% |
8,131,952
| – | – |
|
|
RNAM
14
DELISTED
Avidity Biosciences
RNAM
| $98.5M | 2.23% |
6,416,998
+962,465
| +18% | +$21.2M |
|
15
Rhythm Pharmaceuticals
RYTM
$6.66B
| $98.4M | 2.23% |
5,516,067
| – | – |
|
|
DAWN
16
DELISTED
Day One Biopharmaceuticals
DAWN
| $94.1M | 2.13% |
7,040,622
| – | – |
|
|
BLU
17
DELISTED
BELLUS Health Inc.
BLU
| $91M | 2.06% |
12,643,574
+191,000
| +2% | +$1.48M |
|
|
CVAC
18
DELISTED
CureVac
CVAC
| $85.4M | 1.93% |
+12,245,955
| New | +$107M |
|
|
IMGN
19
DELISTED
Immunogen Inc
IMGN
| $83.9M | 1.9% |
21,853,958
| – | – |
|
20
Wave Life Sciences
WVE
$879M
| $74.5M | 1.69% |
17,202,009
| – | – |
|
|
INBX
21
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $72.7M | 1.65% |
3,853,867
| – | – |
|
|
22
Geron
GERN
$842M
| $68.5M | 1.55% |
31,544,806
+18,614,095
| +144% | +$52.9M |
|
23
Cogent Biosciences
COGT
$5.68B
| $64.7M | 1.47% |
5,999,481
| – | – |
|
|
24
Celldex Therapeutics
CLDX
$3.02B
| $62.4M | 1.41% |
1,734,972
-340,028
| -16% | -$14.7M |
|
25
Acrivon Therapeutics
ACRV
$78.4M
| $61M | 1.38% |
4,810,508
| – | – |
|
Similar funds
AAIS
MG
CC
AI
BMSSC
HTC
WAM
RA Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, RA Capital Management held 73 positions worth $4.42B, down 10% from $4.93B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
RA Capital Management deployed $279M of net new capital in Q1 2023, opening 3 new positions and adding to 13 existing holdings. Its largest new stake was CureVac: 12,245,955 shares worth $85.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Rocket Pharmaceuticals, an estimated $25M trimmed.
- RA Capital Management's largest Q1 2023 buy was CureVac: 12,245,955 shares worth $85.4M.
- RA Capital Management added most to Vaxcyte in Q1 2023, an estimated $60.8M increase.
- RA Capital Management's biggest Q1 2023 reduction was Rocket Pharmaceuticals, cutting an estimated $25M.
- RA Capital Management fully exited Travere Therapeutics in Q1 2023, selling an estimated $83.8M.
- RA Capital Management's ten largest holdings make up 50% of its $4.42B portfolio in Q1 2023.
- RA Capital Management opened 3 new positions and closed 14 in Q1 2023.
- RA Capital Management's portfolio value fell 10% quarter-over-quarter to $4.42B.
Based on RA Capital Management's 13F filing for Q1 2023, filed 15 May 2023.